- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04074941
The Effect of Sodium Reduction on Blood Pressure and Physical Function in Older Adults (SOTRUE)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Hypertension in older adults is a known contributor to both cardiovascular disease and falls. The Centers of Disease Control advocates for low sodium, senior meal plans as a strategy to lower blood pressure (BP). However, sodium is recommended to treat orthostatic hypotension (OH), a risk factor of falls. The long-term effects of low sodium intake on physical function are largely unknown in older adults.
The objective of this proposed pilot study is to determine the feasibility of an individual-level, randomized feeding study that examines the impact of sodium reduction on BP regulation among 40 semi-independent, older adults aged 60 and above.
Primary Aim 1: To determine the effects of a low sodium (<0.9 mg per kcal of energy intake), 2-week meal plan compared with a usual meal plan (average sodium ~2 mg per kcal of energy intake) on seated BP among independently living older adults.
Hypothesis Aim 1: Compared with the usual meal plan, a reduced sodium meal plan will lower seated BP in older adults after 2 weeks.
Feasibility Aim 1: To evaluate the recruitment experience, meal cost, meal delivery logistics, and compliance with and tolerability of the meal plan (urine sodium and palatability questionnaires).
Feasibility Aim 2: To determine effect size (variance) of secondary outcomes: standing BP, OH (standing minus seated BP), orthostatic symptoms, and a timed up and go test (TUG).
Eligible participants will be randomized to low versus usual sodium meal plans for two weeks. Assessments will be made at the in-person baseline visit, one week telephonic interview and 2 week in person follow-up visit.
The primary outcome is seated BP and secondary outcomes include orthostatic hypertension and Timed Up and Go (TUG) tests. Both primary and secondary outcomes will be measured twice: (1) before the study begins (baseline), and (2) after 2 week period. Patient-reported outcomes, dietary compliance, and urine electrolytes will be assessed as well.
Intent-to-treat analysis will be conducted for all endpoints.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Revere, Massachusetts, Forenede Stater, 02151
- Jack Satter House
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Resident at Jack Satter House in Revere
- Age >= 60 years
- Resting systolic blood pressure 100-149 mm Hg and diastolic blood pressure <100 mm Hg
- Stable BP medications (no recent or intended changes)
Exclusion Criteria:
- Cognitive Impairment (Montreal Cognitive Assessment test <18)
- Unstable blood pressure medications in the past 2 months
- Terminal or mental illness
- Severe allergies to common foods
- Unwillingness to comply with the diet
- Physical inability to do a timed up and go test
- Active kidney dialysis or history of kidney transplant
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Low sodium diet
This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
|
Intervention include low sodium or usual sodium diet
|
|
Aktiv komparator: Usual sodium diet
This group will get a usual sodium diet (~2 mg per kcal of energy intake).
|
Intervention include low sodium or usual sodium diet
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Seated Blood Pressure
Tidsramme: 2 weeks
|
Average of three seated systolic and diastolic blood pressure readings
|
2 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Orthostatic Hypotension
Tidsramme: 2 weeks
|
Measured from supine and standing systolic and diastolic blood pressure readings
|
2 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Timed up and go Test
Tidsramme: 2 weeks
|
Participant will be asked to start from seated position, stand up from the chair, walk 3 meters in a straight line, turn, walk back to the chair and sit down.
The investigators will use average of the two trials.
|
2 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Shivani Sahni, PhD, Marcus Institute, Hebrew SeniorLife and Harvard Medical School
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB-2019-22
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forhøjet blodtryk
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Inhibikase TherapeuticsIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
BayerAfsluttet
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
-
Shanghai Zhongshan HospitalIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
Kliniske forsøg med Dietary intervention
-
Nanjing Medical UniversityTilmelding efter invitationMavekræft (GC) | Skrøbelighed i voksenkirurgiKina
-
University of ThessalyRekrutteringMultipel sclerose | Anæmi | IBD | Colitis Ulcerativ | Hypertension (HTN)Grækenland
-
University of VermontAfsluttet
-
University of PrimorskaCommunity Healthcare Center dr. Adolf Drolc Maribor (HCM)Aktiv, ikke rekrutterende
-
Universidad de GranadaRekruttering
-
The Hong Kong Polytechnic UniversityAktiv, ikke rekrutterendeSarkopenisk fedmeHong Kong
-
NeuroEnergy Ventures, Inc.Aktiv, ikke rekrutterende
-
Duke UniversityAktiv, ikke rekrutterendeKronisk nyresygdom | Sygdomsforebyggelse | DiætinterventionerForenede Stater
-
Emory UniversityCenters for Disease Control and PreventionAfsluttetNyretransplantationForenede Stater
-
Biolux Research Holdings, Inc.AfsluttetOrtodontisk tandbevægelseCanada